Literature DB >> 33718156

Evaluation of the Therapeutic Effect of Adjuvant Transcatheter Arterial Chemoembolization Based on Ki67 After Hepatocellular Carcinoma Surgery.

Yu-Fei Zhao1, Xiu Xiong1, Kai Chen1, Wei Tang1, Xu Yang1, Zheng-Rong Shi1.   

Abstract

BACKGROUND AND AIMS: This study aimed to determine the relationship between Ki67 expression and the efficacy of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in patients with hepatocellular carcinoma.
METHODS: The Kaplan-Meier method was used to analyze the recurrence-free survival (RFS) and overall survival (OS) rates between the sub-groups in the ki67 low expression group and the ki67 high expression group and analyze the relationship between the expression of Ki67 and the efficacy of TACE.
RESULTS: After PSM, there was no significant difference in the RFS and OS between the surgery + TACE and surgery subgroups after 1, 2, or 3 years (RFS: 63.9%, 55.6%, and 42.9% vs. 83.3%, 63.9%, and 55.6%, respectively, P = 0.279; OS: 91.7%, 83.3%, and 74.3% vs. 91.7%, 88.9%, and 71.4%, respectively, P = 0.890) in the Ki67 low-expression group. The RFS and OS were higher in the surgery + TACE subgroup than the surgery subgroup after 1, 2, and 3 years (RFS: 80.0%, 77.5%, and 69.2% vs. 53.5%, 39.5%, and 32.6%, respectively, P<0.001; OS: 97.5%, 85.0%, and 79.5% vs. 79.1%, 48.8%, and 42.9%, respectively, P = 0.001) in the Ki67 high expression group. The RFS was higher in the Ki67 high-expression subgroup than the low-expression subgroup after 1, 2, and 3 years, and OS had no significant difference (RFS: 80.0%, 79.5%, and 69.2% vs. 67.4%, 56.5%, and 46.7%, respectively, P = 0.035; OS: 97.5%, 85.0%, and 79.5% vs. 93.5%, 82.6%, and 75.6%, respectively, P = 0.665) in the surgery + TACE group.
CONCLUSIONS: For patients with hepatocellular carcinoma and high expression of Ki67 (Ki67≥20%), adjuvant hepatic artery chemoembolization after radical liver tumor resection effectively reduced the probability of tumor recurrence after surgery and prolonged the OS of patients. High Ki67 expression during the post-operative follow-up evaluation of hepatocellular carcinoma patients is an indicator for adjuvant TACE therapy.
Copyright © 2021 Zhao, Xiong, Chen, Tang, Yang and Shi.

Entities:  

Keywords:  hepatocellular carcinoma (HCC); ki67; postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE); prognosis; propensity score matching (PSM)

Year:  2021        PMID: 33718156      PMCID: PMC7947851          DOI: 10.3389/fonc.2021.605234

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  27 in total

1.  Texture analysis of multi-phase MRI images to detect expression of Ki67 in hepatocellular carcinoma.

Authors:  Y Li; C Yan; S Weng; Z Shi; H Sun; J Chen; X Xu; R Ye; J Hong
Journal:  Clin Radiol       Date:  2019-07-27       Impact factor: 2.350

2.  Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.

Authors:  Shuang Liu; Hui Li; Lei Guo; Bo Zhang; Binghai Zhou; Wentao Zhang; Jian Zhou; Jia Fan; Qinghai Ye
Journal:  Oncologist       Date:  2018-12-14

3.  Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion.

Authors:  Jing Jian Sun; Kang Wang; Cun Zhen Zhang; Wei Xing Guo; Jie Shi; Wen Ming Cong; Meng Chao Wu; Wan Yee Lau; Shu Qun Cheng
Journal:  Ann Surg Oncol       Date:  2015-12-29       Impact factor: 5.344

4.  Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

Authors:  MinKe He; QiJiong Li; RuHai Zou; JingXian Shen; WanQiang Fang; GuoSheng Tan; YuanMin Zhou; XiaoPing Wu; Li Xu; Wei Wei; Yong Le; ZhongGuo Zhou; Ming Zhao; Ying Guo; RongPing Guo; MinShan Chen; Ming Shi
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

5.  Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy.

Authors:  Alton B Farris; Nevra Dursun; Renumathy Dhanasekaran; Ipek Coban; Emily B McIntosh; N Volkan Adsay; Hyun S Kim
Journal:  Pathol Res Pract       Date:  2011-11-15       Impact factor: 3.250

6.  Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus.

Authors:  Bao-Gang Peng; Qiang He; Jia-Ping Li; Fan Zhou
Journal:  Am J Surg       Date:  2009-03-12       Impact factor: 2.565

7.  Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.

Authors:  Parissa Tabrizian; Ghalib Jibara; Brian Shrager; Myron Schwartz; Sasan Roayaie
Journal:  Ann Surg       Date:  2015-05       Impact factor: 12.969

8.  Diagnostic Value of Gd-EOB-DTPA-Enhanced MRI for the Expression of Ki67 and Microvascular Density in Hepatocellular Carcinoma.

Authors:  Yidi Chen; Xiali Qin; Liling Long; Ling Zhang; Zhongkui Huang; Zijian Jiang; Chenhui Li
Journal:  J Magn Reson Imaging       Date:  2019-11-01       Impact factor: 4.813

Review 9.  A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma.

Authors:  Wen Chen; Tao Ma; Jian Zhang; Xiaozhen Zhang; Wei Chen; Yinan Shen; Xueli Bai; Tingbo Liang
Journal:  HPB (Oxford)       Date:  2020-01-21       Impact factor: 3.647

10.  Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion.

Authors:  Han Wang; Peng-Cheng Du; Meng-Chao Wu; Wen-Ming Cong
Journal:  Hepatobiliary Surg Nutr       Date:  2018-12       Impact factor: 7.293

View more
  2 in total

1.  Added Value of Viscoelasticity for MRI-Based Prediction of Ki-67 Expression of Hepatocellular Carcinoma Using a Deep Learning Combined Radiomics (DLCR) Model.

Authors:  Xumei Hu; Jiahao Zhou; Yan Li; Yikun Wang; Jing Guo; Ingolf Sack; Weibo Chen; Fuhua Yan; Ruokun Li; Chengyan Wang
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

2.  Prognostic Value of GPNMB, EGFR, p-PI3K, and Ki-67 in Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Bo Wang; Mengyan Li; Anna Su; Yongmei Gao; Yan Shi; Chao Li; Wenying Liu; Liping Su; Wan Li; Yuqing Ma
Journal:  Anal Cell Pathol (Amst)       Date:  2022-08-31       Impact factor: 4.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.